Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Combination of osimertinib and bevacizumab as first-line treatment for patients with metastatic EGFR-mutant lung cancers - In reply
    Correspondence

    Schoenfeld, A. J.; Yu, H. A.
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • Discovery of IPN60090, a clinical stage selective glutaminase-1 (GLS-1) inhibitor with excellent pharmacokinetic and physicochemical properties
    Journal Article

    Soth, M. J.; Le, K.; Di Francesco, M. E.; Hamilton, M. M.; Liu, G.; Burke, J. P.; Carroll, C. L.; Kovacs, J. J.; Bardenhagen, J. P.; Bristow, C. A.; more...
    Journal of Medicinal Chemistry (2020)

    Fulltext@MSK | Save
  • NRG1 fusion-driven tumors: Biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents
    Review

    Laskin, J.; Liu, S. V.; Tolba, K.; Heining, C.; Schlenk, R. F.; Cheema, P.; Cadranel, J.; Jones, M. R.; Drilon, A.; Cseh, A.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors
    Journal Article

    Shaverdian, N.; Beattie, J.; Thor, M.; Offin, M.; Shepherd, A. F.; Gelblum, D. Y.; Wu, A. J.; Simone, C. B. 2nd; Hellmann, M. D.; Chaft, J. E.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Lorlatinib and bevacizumab activity in ALK-rearranged lung cancers after lorlatinib progression
    Journal Article

    Choudhury, N. J.; Young, R. J.; Sellitti, M.; Miller, A.; Drilon, A.
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save
  • NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
    Journal Article

    Somwar, R.; Hofmann, N. E.; Smith, B.; Odintsov, I.; Vojnic, M.; Linkov, I.; Tam, A.; Khodos, I.; Mattar, M. S.; de Stanchina, E.; more...
    Communications Biology (2020)

    Fulltext@MSK | Save
  • Concurrent mutations in STK11 and KEAP1 promote ferroptosis protection and SCD1 dependence in lung cancer
    Journal Article

    Wohlhieter, C. A.; Richards, A. L.; Uddin, F.; Hulton, C. H.; Quintanal-Villalonga, À; Martin, A.; de Stanchina, E.; Bhanot, U.; Asher, M.; Shah, N. S.; more...
    Cell Reports (2020)

    Fulltext@MSK | Save
  • Circulating tumor DNA as a biomarker in oligometastatic non-small cell lung cancer
    Meeting Abstract

    Lebow, E. S.; Murciano-Goroff, Y.; Razavi, P.; Reis, J. S.; Flynn, J.; Zhang, Z.; Tu, H. Y.; Bertucci, C.; Lim, L. P.; Li, M.; more...
    International Journal of Radiation Oncology, Biology, Physics (2020)

    Fulltext@MSK | Save
  • A phase III randomized trial of pleurectomy/decortication plus chemotherapy with or without adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for malignant pleural mesothelioma (MPM) (NRG-LU006)
    Meeting Abstract

    Rimner, A.; Hu, C.; Zauderer, M.; Yorke, E. D.; Simone, C. B. 2nd; Gill, R. R.; Voong, K. R.; Peikert, T. D.; Tsao, M.; Li, Z.; more...
    International Journal of Radiation Oncology, Biology, Physics (2020)

    Fulltext@MSK | Save
  • Durvalumab with concurrent definitive radiation therapy (DART) for locally-advanced non-small cell lung cancer: A phase II study
    Meeting Abstract

    Rimner, A.; Offin, M.; Shaverdian, N.; McKnight, D.; Li, H.; McCune, M.; Patson, B.; Kotecha, R.; Gomez, D. R.; Chaft, J.
    International Journal of Radiation Oncology, Biology, Physics (2020)

    Fulltext@MSK | Save